CoChat

Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis

Open access
Mao, E. J., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., Ananthakrishnan, A. N. · 2017 · Alimentary Pharmacology & Therapeutics
Cited by 245

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Introduction: Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course leading to hospitalisation and surgery. The ability of existing therapies to alter disease course is not clearly defined. Aim: To investigate the comparative efficacy of currently available inflammatory bowel disease (IBD) therapies to reduce hospitalisation and surgery. Methods: We conducted a systematic review in MEDLINE/PubMed for randomised controlled trials (RCT) published between January 1980 and May 2016 examining efficacy of biological or immunomodulator therapy in IBD. We performed direct comparisons of pooled proportions of hospitalisation and surgery. Pair‐wise comparisons using a random‐effects Bayesian network meta‐analysis were performed to assess comparative efficacy of different treatments. Results: We identified seven randomised controlled trials (5 CD; 2 UC) comparing three biologics and one immunomodulator with placebo. In CD, anti‐TNF biologics significantly reduced hospitalisation [Odds ratio (OR) 0.46, 95% confidence interval (CI) 0.36–0.60] and surgery (OR 0.23, 95% CI 0.13–0.42) compared to placebo. No statistically significant reduction was noted with azathioprine or vedolizumab. Azathioprine was inferior to both infliximab and adalimumab in preventing CD‐related hospitalisation (>97.5% probability). Anti‐TNF biologics significantly reduced hospitalisation (OR 0.48, 95% CI 0.29–0.80) and surgery (OR 0.67, 95% CI 0.46–0.97) in UC. There were no statistically significant differences in the pair‐wise comparisons between active treatments. Conclusions: In CD and UC, anti‐TNF biologics are efficacious in reducing the odds of hospitalisation by half and surgery by 33–77%. Azathioprine and vedolizumab were not associated with a similar improvement, but robust conclusions may be limited due to paucity of RCT s.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.13847

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 245

Metadata

Authors
Mao, E. J., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2016-11-10
Volume
45
Issue
1
Pages
3-13
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2552690718
Cited by
245
References
3
FWCI
2.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. https://app.cochat.ai/papers/10.1111/apt.13847
The paper
Mao, E. J., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017). Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.13847

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.